Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 5:49 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,135 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Dual Care Clear all
Recruiting Phase 3 Interventional

Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML

NCT07007312
View directory record Official record
Conditions
Acute Myeloid Leukemia (AML)
Interventions
Ziftomenib, Placebo, Venetoclax, Azacitidine (AZA), Daunorubicin, Cytarabine (Ara-C)
Drug
Lead sponsor
Kura Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
44
States / cities
Gilbert, Arizona • Clovis, California • La Jolla, California + 37 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 21, 2026, 5:49 PM EDT
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

Truway Whole-Body Digital Twin and Physiologic Resilience Study (TRU-OMNIBODY)

NCT07805044
View directory record Official record
Conditions
PHYSIOLOGICAL PHENOMENA, Homeostasis, Physical Functional Performance, Cardiorespiratory Fitness, Cardiometabolic Risk Factors, Mobility Limitation
Interventions
Standardized Physiologic Resilience Challenge, Multimodal Whole-Body Physiologic Monitoring, Research-Only Whole-Body Digital Twin Analysis
Procedure · Other
Lead sponsor
Truway Health, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
450 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2041
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 21, 2026, 5:49 PM EDT
Active, not recruiting Phase 3 Interventional Results available

Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer

NCT00433511
View directory record Official record
Conditions
Breast Adenocarcinoma
Interventions
Bevacizumab, Cyclophosphamide, Doxorubicin Hydrochloride, Laboratory Biomarker Analysis, Paclitaxel, Placebo Administration, Quality-of-Life Assessment
Biological · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
4,994 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2027
U.S. locations
840
States / cities
Anniston, Alabama • Birmingham, Alabama • Mobile, Alabama + 548 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 21, 2026, 5:49 PM EDT
Completed Not applicable Interventional

SAVEPACe - Search AV Extension and Managed Ventricular Pacing for Promoting Atrio-Ventricular Conduction

NCT00284830
View directory record Official record
Conditions
Sick Sinus Syndrome, Heart Failure, Congestive, Atrial Fibrillation, Bradycardia, Ventricular Dysfunction
Interventions
Implantable Pulse Generators
Device
Lead sponsor
Medtronic Cardiac Rhythm and Heart Failure
Industry
Eligibility
18 Years and older
Enrollment
1,070 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
63
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Conway, Arkansas + 60 more
Source: ClinicalTrials.gov public record
Updated Feb 29, 2008 · Synced Oct 21, 2026, 5:49 PM EDT
Completed Phase 3 Interventional

A Trial to Learn How Well Finerenone Works and How Safe it is in Adult Participants With Non-diabetic Chronic Kidney Disease

NCT05047263
View directory record Official record
Conditions
Non-diabetic Chronic Kidney Disease
Interventions
Finerenone (BAY94-8862), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
1,584 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
57
States / cities
Huntsville, Alabama • Chula Vista, California • El Centro, California + 49 more
Source: ClinicalTrials.gov public record
Updated Feb 13, 2026 · Synced Oct 21, 2026, 5:49 PM EDT
Withdrawn Phase 2 Interventional

Axatilimab Plus Standard of Care Therapy for the Prevention of Graft Versus Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Hematologic Cancer, ABRAXAS Trial

NCT07349771
View directory record Official record
Conditions
Hematopoietic and Lymphatic System Neoplasm
Interventions
Allogeneic Hematopoietic Stem Cell Transplantation, Axatilimab, Biospecimen Collection, Bone Marrow Aspiration, Computed Tomography, Cyclophosphamide, Magnetic Resonance Imaging, Mycophenolate Mofetil, Placebo Administration, Positron Emission Tomography, Skin Biopsy, Tacrolimus, X-Ray Imaging
Procedure · Biological · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
3
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 21, 2026, 5:49 PM EDT
Not listed Phase 2Phase 3 Interventional

A Multi-Center Study on the Use of Rho-Kinase Inhibitor to Reduce or Prevent PVR in RRD Eyes at High Risk for PVR

NCT05660447
View directory record Official record
Conditions
Rhegmatogenous Retinal Detachment, Proliferative Vitreoretinopathy
Interventions
Netarsudil 0.02% Ophthalmic Solution [RHOPRESSA], Glycerin 0.2%/Hypromellose 0.2%/Peg 1%/Soln,Oph,Ud
Drug
Lead sponsor
Wills Eye
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 30, 2024 · Synced Oct 21, 2026, 5:49 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Mepolizumab Adjunctive Therapy in Participants With Severe Eosinophilic Asthma on Markers of Asthma Control

NCT02281318
View directory record Official record
Conditions
Asthma
Interventions
Mepolizumab, Placebo, SOC
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years and older
Enrollment
556 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
24
States / cities
Birmingham, Alabama • Fresno, California • Long Beach, California + 20 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2018 · Synced Oct 21, 2026, 5:49 PM EDT
Not listed Phase 4 Interventional

Study to Reduce Symptoms of Premature Beats With Ranolazine

NCT01996618
View directory record Official record
Conditions
Premature Ventricular Beats
Interventions
Ranolazine
Drug
Lead sponsor
Walter Reed National Military Medical Center
Federal
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 1, 2015 · Synced Oct 21, 2026, 5:49 PM EDT
Completed Not applicable Interventional

An Exploratory, Double-arm, 8-week Study to Explore the Feasibility and Acceptability of Abbreviated Treatment with CT-156 in People with Schizophrenia.

NCT06486948
View directory record Official record
Conditions
Schizophrenia
Interventions
CT-156
Device
Lead sponsor
Click Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 9, 2025 · Synced Oct 21, 2026, 5:49 PM EDT
Completed Phase 3 Interventional Results available

A Study to Learn How Well a Higher Amount of Aflibercept Given as an Injection Into the Eye Works and How Safe it is in People With Reduced Vision Due to Swelling in the Macula, Central Part of the Retina Caused by a Blocked Vein in the Retina (Macula Edema Secondary to Retinal Vein Occlusion)

NCT05850520
View directory record Official record
Conditions
Macular Edema Secondary to Retinal Vein Occlusion
Interventions
Aflibercept, VEGF Trap-Eye(Eylea, BAY86-5321)_higher dose, Aflibercept, VEGF Trap-Eye(Eylea, BAY86-5321)_2 mg, Sham, Fluorescein
Drug · Diagnostic Test
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
892 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
53
States / cities
Fullerton, California • Long Beach, California • Mountain View, California + 48 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Oct 21, 2026, 5:49 PM EDT
Completed Phase 2 Interventional Results available

Dasatinib Added to Gemcitabine for Subjects With Locally-advanced Pancreatic Cancer

NCT01395017
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
dasatinib, Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years and older
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
11
States / cities
Birmingham, Alabama • Los Angeles, California • Orange, California + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2016 · Synced Oct 21, 2026, 5:49 PM EDT
Completed Phase 3 Interventional Results available

RESET Trial - Part 1 - A Phase 3 Trial in Subjects With Sjögren-Larsson Syndrome (SLS)

NCT03445650
View directory record Official record
Conditions
Sjogren-Larsson Syndrome
Interventions
ADX-102 1% Topical Dermal Cream (reproxalap), Vehicle of ADX-102 Topical Dermal Cream
Drug
Lead sponsor
Aldeyra Therapeutics, Inc.
Industry
Eligibility
3 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
2
States / cities
New Haven, Connecticut • Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Feb 9, 2023 · Synced Oct 21, 2026, 5:49 PM EDT
Completed Not applicable Interventional Results available

Lower Limb Prostheses for Individuals Who Carry Infants, Toddlers, and Other Loads

NCT07159490
View directory record Official record
Conditions
Amputation, Prosthesis User
Interventions
Standard-of-care prosthetic foot, Standard-of-care prosthetic foot with heel-stiffening wedge, Standard-of-care prosthetic foot of one category greater stiffness, Dual keel prosthetic foot, Powered ankle-foot
Device
Lead sponsor
VA Puget Sound Health Care System
Federal
Eligibility
18 Years to 70 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Oct 21, 2026, 5:49 PM EDT
Completed Not applicable Interventional Results available

Pilot Study to Improve Care Coordination

NCT02386189
View directory record Official record
Conditions
Chronic Illness
Interventions
Patient Care Coordination Training
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Aug 28, 2019 · Synced Oct 21, 2026, 5:49 PM EDT
Completed Not applicable Interventional

Probiotics in Primary Care

NCT01254097
View directory record Official record
Conditions
Antibiotic Side Effect
Interventions
Probiotic
Dietary Supplement
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years to 79 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 25, 2015 · Synced Oct 21, 2026, 5:49 PM EDT
Completed Phase 4 Interventional Results available

EDUCATE: The MEDTRONIC Endeavor Drug Eluting Stenting: Understanding Care, Antiplatelet Agents and Thrombotic Events

NCT01069003
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Placebo Arm, Thienopyridine Therapy, Surveillance Arm
Drug · Device
Lead sponsor
Medtronic Vascular
Industry
Eligibility
19 Years and older
Enrollment
2,272 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Anderson, South Carolina
Source: ClinicalTrials.gov public record
Updated Jan 20, 2016 · Synced Oct 21, 2026, 5:49 PM EDT
Terminated Phase 2 Interventional

AT1001 for the Treatment of COVID-19 Related MIS-C

NCT05022303
View directory record Official record
Conditions
Covid19, Multisystem Inflammatory Syndrome in Children
Interventions
Larazotide Acetate, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
1 Month to 21 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 13, 2024 · Synced Oct 21, 2026, 5:49 PM EDT
Not listed Phase 3 Interventional

A Study of Regorafenib in Refractory Advanced Gastro-Oesophageal Cancer

NCT02773524
View directory record Official record
Conditions
Gastro-Oesophageal Cancer
Interventions
Regorafenib, Placebo
Drug · Other
Lead sponsor
Australasian Gastro-Intestinal Trials Group
Network
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
4
States / cities
Scottsdale, Arizona • Los Angeles, California • Urbana, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2022 · Synced Oct 21, 2026, 5:49 PM EDT
Completed Phase 2 Interventional

Study Evaluating the Safety and Efficacy of MN-221 as an Adjunct to Standard Therapy in Subjects Experiencing an Acute Exacerbation of Asthma

NCT00838591
View directory record Official record
Conditions
Asthma
Interventions
MN-221, Placebo
Drug
Lead sponsor
MediciNova
Industry
Eligibility
18 Years to 65 Years
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
15
States / cities
Loma Linda, California • San Diego, California • Sylmar, California + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2013 · Synced Oct 21, 2026, 5:49 PM EDT
Terminated Not applicable Interventional Results available

Dual Antiplatelet Therapy Adherence With Reminder App Usage

NCT05071027
View directory record Official record
Conditions
Aneurysm Cerebral (Unruptured)
Interventions
Endovascular Neurosurgery
Other
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 15, 2024 · Synced Oct 21, 2026, 5:49 PM EDT
Terminated Phase 3 Interventional

EN3285 for the Prevention or Delay of Oral Mucositis in Patients With Head and Neck Cancer

NCT00574860
View directory record Official record
Conditions
Oral Mucositis, Head and Neck Cancer
Interventions
EN3285, Placebo, Standard of care
Drug · Other
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
2
States / cities
Louisville, Kentucky • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 20, 2013 · Synced Oct 21, 2026, 5:49 PM EDT
Completed Phase 2Phase 3 Interventional Results available

A Multi-Center Trial To Evaluate The Safety And Efficacy Of Pegaptanib Sodium(Macugen) Injected Into The Eye Every 6 Weeks For Up To 2 Years For Macular Swelling Associated With Diabetes, With An Open-Label Macugen Year Extension.

NCT00605280
View directory record Official record
Conditions
Macular Edema Associated With Diabetes Mellitus
Interventions
Standard of Care, Macugen
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
317 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
28
States / cities
Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 24 more
Source: ClinicalTrials.gov public record
Updated Nov 16, 2018 · Synced Oct 21, 2026, 5:49 PM EDT
Completed Phase 3 Interventional Results available

Proxalutamide (GT0918) Treatment for Outpatients With Mild or Moderate COVID-19 Illness

NCT04870606
View directory record Official record
Conditions
Efficacy and Safety
Interventions
Proxalutamide (GT0918), Placebo
Drug
Lead sponsor
Suzhou Kintor Pharmaceutical Inc,
Industry
Eligibility
18 Years and older
Enrollment
733 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
8
States / cities
Phoenix, Arizona • Long Beach, California • Sandy Springs, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 2, 2024 · Synced Oct 21, 2026, 5:49 PM EDT